Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity

Cell signaling initiated at the epidermal growth factor receptor (EGFR), RAS oncoproteins, or PI3K contributes to a common pathway that promotes tumor survival after radiation-induced DNA damage. Inhibition of signaling at the level of EGFR, RAS, and PI3K has been tested, but clinical applicability...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Vol. 68; no. 14; p. 5915
Main Authors:	Prevo, Remko, Deutsch, Eric, Sampson, Oliver, Diplexcito, Julie, Cengel, Keith, Harper, Jane, O'Neill, Peter, McKenna, W Gillies, Patel, Sonal, Bernhard, Eric J
Format:	Journal Article
Language:	English
Published:	United States 15.07.2008
Subjects:	Cell Cycle Cell Line, Tumor DNA Damage Drug Screening Assays, Antitumor Enzyme Inhibitors - pharmacology Flow Cytometry - methods Furans - pharmacology G2 Phase Histones - metabolism Humans Phosphoinositide-3 Kinase Inhibitors Phosphorylation Pyridines - pharmacology Pyrimidines - antagonists & inhibitors Pyrimidines - pharmacology Radiation Tolerance Radiation-Sensitizing Agents - pharmacology
ISSN:	1538-7445, 1538-7445
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!